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Zolpidem, a GABAA receptor-positivemodulator, is the gold-standard drug for treating insomnia. Zolpidem prolongs IPSCs to decrease
sleep latency and increase sleep time, effects that depend on2 and/or3 subunit-containing receptors. Compared with natural NREM
sleep, zolpidemalsodecreases theEEGpower, aneffect thatdependson1 subunit-containing receptors, andwhichmaymakezolpidem-
induced sleep less optimal. In this paper, we investigate whether zolpidem needs to potentiate only particular GABAergic pathways to
induce sleep without reducing EEG power. Mice with a knock-in F77I mutation in the GABAA receptor 2 subunit gene are zolpidem-
insensitive. Using these mice, GABAA receptors in the frontal motor neocortex and hypothalamic (tuberomammillary nucleus)
histaminergic-neurons of2I77miceweremade selectively sensitive to zolpidemby genetically swapping the2I77 subunitswith2F77
subunits. When histamine neurons were made selectively zolpidem-sensitive, systemic administration of zolpidem shortened sleep
latency and increased sleep time. But in contrast to the effect of zolpidem onwild-typemice, the power in the EEG spectra of NREM sleep
was not decreased, suggesting that these EEG power-reducing effects of zolpidem do not depend on reduced histamine release. Selective
potentiationofGABAA receptors in the frontal cortex by systemic zolpidemadministration also reduced sleep latency, but less so than for
histamine neurons. These results could help with the design of new sedatives that induce a more natural sleep.
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Introduction
Many healthy people who cannot sleep, as well as many with
neurological or mental illness, take sedatives (Wafford and Ebert,
2008; Winsky-Sommerer, 2009; Nutt and Stahl, 2010; Mignot,
2013; Rihel and Schier, 2013). Zolpidem (Ambien), a nonbenzo-
diazepine GABAA receptor-positive modulator, is currently the
most successful “sleeping pill” (Nutt and Stahl, 2010). In the
United States alone, there were 53.4 million prescriptions for
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Significance Statement
Many people who find it hard to get to sleep take sedatives. Zolpidem (Ambien) is the most widely prescribed “sleeping pill.” It
makes the inhibitory neurotransmitter GABA work better at its receptors throughout the brain. The sleep induced by zolpidem
does not resemble natural sleep because it produces a lower power in the brain waves that occur while we are sleeping. We show
usingmouse genetics that zolpidem only needs to work on specific parts and cell types of the brain, including histamine neurons
in the hypothalamus, to induce sleep but without reducing the power of the sleep. This knowledge could help in the design of
sleeping pills that induce a more natural sleep.
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zolpidem in 2010 (Greenblatt and Roth, 2012). The drug de-
creases sleep latency, the time to the onset of NREM sleep (Arbilla
et al., 1985; Gottesmann et al., 1998; Alexandre et al., 2008; Ana-
clet et al., 2012; Xu et al., 2014). After taking a 10 mg tablet of
zolpidem, the average person goes to sleep after12 min (Green-
blatt and Roth, 2012). Compared with natural (drug-free) NREM
sleep, however, the NREM sleep induced by zolpidem has re-
duced power in most EEG frequencies (Landolt et al., 2000; Kopp
et al., 2004; Alexandre et al., 2008). This reduced power may
indicate that zolpidem-induced sleep is suboptimal compared
with natural NREM sleep.
Zolpidem works at three GABAA receptor subtypes: 12,
22, and 32 (Pritchett and Seeburg, 1990; Crestani et al.,
2000; Cope et al., 2004; Kopp et al., 2004; Leppa¨ et al., 2011), and
has the highest affinity at 1-containing receptors (Pritchett and
Seeburg, 1990). These12-containing receptors are expressed
widely (Niddam et al., 1987; Wisden et al., 1988, 1992; Pritchett et
al., 1989; Duncan et al., 1995; Fritschy and Mohler, 1995; Ho¨rt-
nagl et al., 2013). Surprisingly, the 1-containing GABA recep-
tors are not responsible for zolpidem’s ability to promote sleep.
In mice with 1 subunits made insensitive to zolpidem by a mu-
tation, H101R, zolpidem reduces latency to NREM sleep and
prolongs NREM sleep time as well as it does in wild-type mice
(Kopp et al., 2004). Thus, zolpidem’s sleep-promoting effects
come from enhancing GABA’s actions at GABAA receptors with
2 and/or 3 subunits. Instead, the 1H101R mice do show that
1-containing receptors are needed for zolpidem to produce its
characteristic decrease in the EEG power in NREM sleep (Kopp et
al., 2004). But can zolpidem potentiate 2 and/or 3-containing
receptors in only particular GABA pathways to induce sleep with-
out reducing EEG power? The answer could help design sedatives
that produce a more natural sleep.
Natural NREM sleep is hypothesized to start when GABA
neurons in the preoptic hypothalamus increase their activity
onto, among other targets, the wake-promoting histaminergic
neurons in the tuberomammillary nucleus (TMN) of the poste-
rior hypothalamus (Nitz and Siegel, 1996; Sherin et al., 1996,
1998; Zhang et al., 2015). Infusing the GABAA agonist muscimol
into this area induces sleep (Lin et al., 1989; Nitz and Siegel,
1996); conversely, injecting GABAA receptor antagonists there
decreases the potency of GABAergic anesthetics (Nelson et al.,
2002). Thus, GABAA receptor modulators, such as zolpidem,
could produce sleep by decreasing histaminergic activity (Nelson
et al., 2002). Histaminergic neurons express132 and232
GABAA receptors (Fritschy and Mohler, 1995; Sergeeva et al.,
2002; Zecharia et al., 2009, 2012; May et al., 2013); and so, GABAA
receptors on these neurons could, in part, account either for the
EEG power-reducing effect of zolpidem (1-containing recep-
tors), or critically, the ability of zolpidem to reduce latency to
NREM sleep and increase sleep time (2-containing receptors).
We previously used a pharmacogenetics method, based on
mutated GABAA receptors, for probing how endogenous GABA
inputs onto selected cell types generates behavior (Wulff et al.,
2007; Wisden et al., 2009; Sieghart, 2012). The mutation F77I in
the 2 subunit (2I77) abolishes zolpidem binding to GABAA
receptors (Buhr et al., 1997; Wingrove et al., 1997; Cope et al.,
2004). In 2I77 lox mice, the zolpidem-insensitive 2I77 subunits
can be swapped with zolpidem-sensitive2F77 versions (Wulff et
al., 2007). Here, using this method, we found that strengthening
inhibition onto histamine neurons by zolpidem induces NREM
sleep but does not reduce EEG power.
Materials andMethods
Mice. All experiments were performed in accordance with the United
Kingdom Home Office Animal Procedures Act (1986); all procedures
were approved by the Imperial College Ethical Review Committee. All
mice weighed between 19 and 30 g and were17 weeks old at the time of
AAV injections. Both male and female mice were used, but no sex differ-
ences were observed and the data were pooled. The sleep–wake studies
and drug administrations were started4 weeks after AAV injection (see
below). Adult C57BL/6J mice were purchased from Harlan. The HDC-
2I77 mice were produced by crossing HDC-Cre (JAX stock #021198,
RRID:IMSR_JAX:021198) and 2I77lox- (zolpidem-insensitive) mice
(JAX stock #021197, RRID:IMSR_JAX:021197) on C57BL/6J back-
grounds, as described previously (Zecharia et al., 2012). In adult HDC-
Cre mice, Cre recombinase expression is driven by the endogenous hdc
gene and is found selectively in histaminergic neurons in the TMN, and
mast cells in the rest of the brain; the knock-in HDC-Cre allele expresses
functional HDC protein (Zecharia et al., 2012). In the 2I77lox-mice,
exon 4 of the GABAA receptor 2 subunit gene ( gabrg2), which encodes
the critical I77 residue, is flanked by loxP sites (Wulff et al., 2007); dele-
tion of exon 4 by Cre recombinase produces a null gabrg2 allele (Wulff et
al., 2007, 2009a, b; Rovo´ et al., 2014). The baseline vigilance-state data (%
Wake, NREM, and REM) recorded for a 2 h period, as determined by
EEG/EMG scoring, for the mice in drug-free conditions are shown in
Table 1 (see EEG recordings and sleep scoring).
Generation of HDC-2F77, FC-2F77, and superior colliculi (SC) SC-
2F77 mice. Stereotaxic injections of AAV were performed with a Leica
Angle Two frame under isoflurane anesthesia, using Hamilton microliter
#701 10 l syringes with adjoining capillary glass pipettes tapered 1 mm
to 50 m diameter, back-loaded with mineral oil and AAV mixture
(1:1 with 20% mannitol) in the tip (see AAV transgenes and AAV pro-
duction). The coordinates of the (bilateral) injection sites according to
the digital atlas of the Leica apparatus were, relative to bregma: frontal
cortex (FC) of 2I77 lox mice (mediolateral1.75, anteroposterior 1.87,
dorsoventral1.70 (mm), 1.5lAAV-Cre-2A-2F77 andAAV-flex-rev-
EGFP suspension per side, with the two AAVs mixed 1:1 before injec-
tion); SC of 2I77lox mice (mediolateral 1, anteroposterior 3.88,
dorsoventral 2 (mm), 1 l AAV-Cre-2A-2F77 suspension per side);
TMN of HDC-2I77 mice (mediolateral 0.92, anteroposterior
2.70, dorsoventral5.34 (mm), 1.5l AAV- flex-rev-2F77-2A-Venus
suspension per side). After AAV injections, the mice recovered for a
minimum of 4 weeks in their home cages. The baseline vigilance-state
data (% Wake, NREM, and REM), as determined by EEG/EMG scoring,
for the HDC-2F77, FC-2F77, and SC-2F77 mice in drug-free condi-
tions for a 2 h period are shown in Table 1 (see EEG recordings and sleep
scoring).
AAV transgenes and AAV production. The AAV-panpromoter-flex-rev-
Venus-2A-2F77 transgene was constructed from components of pAAV-
CAG-promoter-Cre-2A-2F77, kindly provided by Zoltan Nusser,
Table 1. Time and percentage of time spent inWake, NREM, and REM sleep for the different types of mice used in the studya
Genotype
Wake NREM REM
Time (min) % SEM Time (min) % SEM Time (min) % SEM
C57BL/6J 68.83 57.88 10.38 44.25 37.17 8.00 5.92 4.96 3.01
2I77lox 64.00 54.92 4.68 46.50 39.72 4.47 6.33 5.36 1.74
HDC-2F77 71.58 60.72 5.86 39.08 33.23 5.96 7.08 6.05 1.56
FC-2F77 54.83 47.08 3.48 54.50 46.68 3.50 7.33 6.24 1.38
SC-2F77 64.17 56.12 6.21 46.21 40.45 0.97 3.92 3.43 1.73
aThe data were recorded over a baseline period of 2 h. One-way ANOVA revealed no significant differences between the mouse types for Wake, NREM, or REM sleep.
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Institute of Experimental Medicine, Hungarian Academy of Sciences,
Budapest, Hungary (Sumegi et al., 2012); and pAAV-flex-rev-hM4-
mCherry (Addgene plasmid 44362, gift of Bryan Roth, University of
North Carolina at Chapel Hill, NC (Krashes et al., 2011), Addgene,
RRID:SCR_002037). The “panpromoter” in the AAV-panpromoter-flex-
rev-2F77-2A-Venus transgene was derived from a fragment of the pro-
moter of the mouse histidine decarboxylase (hdc) gene; we originally
hoped that this hdc promoter fragment would be selective for histamin-
ergic cells but found that it worked well in all neuronal cell types we tested
(unpublished data). The AAV-panpromoter-flex-rev-2F77-2A-Venus
transgene plasmid has been deposited at Addgene (Addgene Plasmid
71410, Addgene, RRID:SCR_002037). The AAV-flex-rev-EGFP trans-
gene was Addgene plasmid 28304 (gift from Edward Boyden, Massachu-
setts Institute of Technology, Cambridge, MA). The AAV transgenes
AAV-flex-rev-2F77-2A-Venus, AAV-Cre-2A-2F77, and AAV-flex-rev-
EGFP were each packaged in AAV1/2 capsids and purified with heparin
columns (Klugmann et al., 2005). AAV was suspended in sterile PBS at
1:1 concentration.
EEG recordings and sleep scoring. For nontethered EMG and EEG re-
cordings, mice were fitted with Neurologger 2A devices (Anisimov et al.,
2014). The recordings took place in home cages. Data were sampled at
200 Hz and downloaded offline and processed with Spike2 software
(Cambridge Electronic Design, Spike2 Software, RRID:SCR_000903).
The EEG was high-pass filtered (0.5 Hz corner frequency, 3 dB). The
EMG was bandpass filtered (5– 45 Hz, 3 db). Wake, non-REM, and
REM were first automatically sleep-scored using previously described
criteria (Costa-Miserachs et al., 2003). The EEG results were then man-
ually verified.
To calculate power spectra, segments of NREM identified after sleep
scoring were concatenated and power spectra calculated using a Fast
Fourier transform with a Hanning window function. Segments of data of
at least 10 min were used. The power spectra were normalized as we
described previously, such that the area under the saline controls for a
given genotype was unity (Zhang et al., 2015).
Power changes were computed as differences
in areas under the power spectra.
Behavioral experiments and drug adminis-
tration. Mice were maintained on a 12 h
light/12 h dark cycle with ad libitum food and
water. All behavioral experiments took place
during the “lights off” part of the cycle when
the mice were most active. In all cases, we
used paired comparisons where the animals
served as their own controls, a within-
animals approach (crossover design). The
experimenters were not blinded to treat-
ment. Zolpidem (Tocris Biosciences) was
dissolved in equimolar tartaric acid (BDH
Chemicals) in 0.9% w/v saline.
Immunohistochemistry. Mice were anesthe-
tized with pentobarbital and transcardially per-
fused with PBS followed by 4% PFA. Brains were
submerged in 4% PFA overnight and stored in
30% sucrose. Free-floating sections (40m) were
blocked with 10% normal goat serum, 1% BSA,
0.1% Triton X in PBS (2 h, room temperature).
Sections were incubated for 24–48 h at 4°C with
primary antisera: rabbit anti-Cre (1:1000; Nova-
gen), or rabbit anti-GFP (1:1000; Stratagene), or
rabbit streptavidin (1:1000; Alexa-Fluor-555
conjugate; Invitrogen). Secondary goat anti-
rabbit antisera (Alexa-Fluor-488 or 594, 1:1000;
Invitrogen) were incubated for 2 h at room tem-
perature. Pictures were taken using a Nikon
eclipse 80i microscope with Qcapture Pro soft-
ware (Q Capture software, RRID:SCR_014432),
or a Zeiss Cell Observer Live Cell Imaging Sys-
tem, or a Zeiss LSM 510 inverted microscope
with Zen pro software. Images were processed us-
ing ImageJ (open source, ImageJ, RRID:
SCR_003070) and Adobe Photoshop (Adobe Photoshop CS6, RRID:
SCR_014199).
Quantifying the spread of AAV transduction. For the HDC-2F77 mice,
Venus-positive neurons were counted on fixed sections using ImageJ.
Signal-emitting outliers (15 m or30 m diameter) were excluded,
as were objects visually scored as incorrect (e.g., microglia). For the FC-
2F77 and SC-2F77 mice, Cre-positive neurons were identified by im-
munohistochemistry, and the percentage area of the target region (FC or
SC) was calculated, again using ImageJ (ImageJ, RRID:SCR_003070).
Brain-slice electrophysiology. We recorded spontaneous IPSCs from
whole-cell, voltage-clamped, HDC neurons of the TMN and pyramidal
neurons of the FC in acute slices. Brains were rapidly removed and im-
mersed in ice-cold slicing ACSF (85 mM NaCl, 2.5 mM KCl, 1 mM CaCl2,
5 mM MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, 75 mM sucrose, 11 mM
glucose, bubbled with 95% O2/5% CO2). For the TMN, a tissue block was
cut between the cerebellum and optic tract, and coronal sections were cut
to a thickness of 250 m on a vibratome. For the FC, a tissue block was
cut between the optic tract and1 mm behind the olfactory bulb. After
slicing, the holding chamber was transferred to a 37°C heat block for 15
min, and slicing ACSF was gradually exchanged for recording ACSF (125
mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1.25 mM NaH2PO4, 26
mM NaHCO3, and 11 mM glucose, pH 7.4, bubbled with 95% O2/5%
CO2) over 40 min. Electrophysiological recordings were made at room
temperature. We identified histaminergic neurons by the presence of
hyperpolarization-activated currents (Ih), a transient outward current,
and the spontaneous firing activity of the cells (Stevens et al., 2001).
Virally transduced pyramidal neurons in the FC were found by Cre-
dependent expression of EGFP. Pyramidal neurons were identified pri-
marily by morphology. For detection of IPSCs, we performed whole-cell
recordings in voltage-clamp (70 mV) using internal pipette solutions
containing the following: 140 mM CsCl, 4 mM NaCl, 0.5 mM CaCl2, 10 mM
Figure 1. Zolpidem reduces sleep latency and increases sleep time in C57BL/6J but not in 2I77lox mice. Sleep latencies after
saline and zolpidem (5 mg/kg) injections in C57BL/6J (A) and2I77 lox (B) mice. For C57BL/6Jmice: **p 0.008 (paired t test).
C, Time spent in NREM sleep in the first 45min after saline and zolpidem in C57BL/6J (C) and2I77 lox (D)mice. For C57BL/6Jmice:
***p 0.0003 (paired t test).
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HEPES, 5 mM EGTA, and 2 mM Mg-ATP; the pH was adjusted to 7.3 with
CsOH.
Statistical analysis. For behavioral and EEG comparisons, and compar-
isons of IPSC decay times from the electrophysiology analysis, we used
two-tailed paired t tests (Janusonis, 2009), and normality was assumed.
Analyses were performed in OriginPro 8.6 or GraphPad Prism 4.03
(GraphPad Prism, RRID:SCR_002798).
Results
Zolpidem does not induce sleep in 2I77 lox mice
The wild-type 2 subunit (2F77) confers zolpidem sensitivity
on 1, 2, and 3 subunit-containing GABAA receptors
(Pritchett et al., 1989; Pritchett and Seeburg, 1990; Gu¨nther et al.,
1995). The binding site for zolpidem, at the interface between the
 and2 subunits, requires residue F77 in the2 subunit (Buhr et
al., 1997; Wingrove et al., 1997). Changing the F77 residue to I
(F77I) abolishes zolpidem binding. Consequently, knock-in mice
with the 2 point mutation 2F77I (2I77lox mice) are behavior-
ally insensitive to zolpidem in the dose range 1–30 mg/kg (Cope
et al., 2004; Wulff et al., 2007; Leppa¨ et al., 2011). However, EEG
and sleep responses of 2I77lox mice following zolpidem admin-
istration have not been investigated. C57BL/6J mice and 2I77lox
mice showed no difference in their baseline sleep parameters
(Table 1). We then established how zolpidem (5 mg/kg), com-
pared with a saline injection, influenced latency to NREM-like
sleep and total sleep time in C57BL/6J mice and 2I77lox mice.
Zolpidem at 5 mg/kg (systemic injection, i.p.) caused C57BL/6J
(2F77) mice to enter NREM sleep in 2.6  0.6 min (n  5;
paired t test, t(4) 4.9, p 0.008) (Fig. 1A), whereas at this dose
of zolpidem, 2I77lox mice did not fall asleep for 39 7 min (n
6; paired t test, t(5) 0.31, p 0.77) (Fig. 1B), which was approx-
imately the same time they and C57BL/6J mice took to fall into
NREM sleep following a saline injection (Fig. 1A). In C57BL/6J
mice, in the first 45 min after injection, zolpidem more than
doubled the amount of NREM-like sleep over baseline (from
12 1.6 min to 33 2 min; n 5; paired t test t(4) 20.77, p
0.0003; Fig. 1C). The effect persisted until at least 90 min after
injection. These data, reduced sleep latency and prolonged sleep
time, are consistent with previous reports on zolpidem’s action in
C57BL/6J mice (Kopp et al., 2004; Alexandre et al., 2008). By
contrast, there was no change in the sleep time above baseline in
zolpidem-injected 2I77lox mice (n 6 paired t test, t(5) 0.18,
p  0.86; Fig. 1D). Examples of the primary EEG/EMG record-
ings for saline- and zolpidem-injected C57BL/6 (2F77) and
2I77lox mice are shown in Figure 2.
In agreement with previous studies (Kopp et al., 2004; Alex-
andre et al., 2008), we found that the power of “NREM sleep”
produced by zolpidem in C57BL/6J mice was lower than that
found in natural NREM sleep. Zolpidem reduced power during
NREM sleep (Fig. 3A) over the frequency range between 5 and 16
Hz (n  5, paired t test, t(4)  4.5, p  0.01). In 2I77
lox mice,
zolpidem injection did not change the EEG power spectrum in
either the waking (Fig. 3B) or NREM (Fig. 3C) states.
Potentiation of GABA inputs onto histaminergic neurons by
zolpidem induces andmaintains NREM sleep
Having demonstrated that 2I77lox mice do not enter NREM
sleep after systemic zolpidem administration, we next made sev-
eral areas of the brains of 2I77lox mice zolpidem-sensitive using
the 2I77 to 2F77 subunit switch. The first target was histamine
neurons. Previously, we generated and studied HDC-2I77
mice, which are mice with a deletion of the 2I77 subunit from
histaminergic neurons in the TMN, obtained by crossing HDC-
Cre and 2I77lox mice (Zecharia et al., 2012). The histaminergic
neurons of these HDC-2I77 mice lack IPSCs (Zecharia et al.,
2012). Because the HDC-2I77 mice still had Cre recombinase
expressed in their histaminergic neurons, we could implement a
“restorative genetics” strategy and put the 2F77 subunit back
into the neurons from which the 2I77 version was deleted. We
introduced the zolpidem-sensitive 2F77 subunit into the hista-
minergic neurons of HDC-2I77 mice using a Cre recombinase
flex switch-dependent transgene (Atasoy et al., 2008), flex-rev-
4
Figure2. EEG spectra and sleep scoring for zolpidem-induced sleep inC57BL/6 (2F77)mice
comparedwith2I77 lox mice. A, EEG power spectra for C57BL/6Jmice injectedwith saline or 5
mg/kg zolpidem. The spectra are aligned in register with the / power ratio, the root mean
square electromyogram (RMS EMG), the primary EEG, and the sleep scoring assignments
(Wake, NREM, REM). Arrow indicates the time of saline or zolpidem injection. B, EEG
power spectra for 2I77 lox mice injected with saline or 5 mg/kg zolpidem. All alignments
of traces are as above in A.
Figure 3. Zolpidem does not induce sleep in 2I77lox mice–EEG power analysis. A, EEG
power spectrum of natural NREM sleep (blue) or zolpidem-induced sleep (5 mg/kg, red) in
C57BL/6J(2F77) mice. Zolpidem reduced power during NREM sleep (Fig. 3A) over the fre-
quency range between 5Hz and 16Hz (n 5, paired t test, t(4) 4.5, p 0.01).B, EEG power
spectrumof2I77loxmice (n6) in thewaking state following saline intraperitoneal injection
(black) or zolpidem (5 mg/kg i.p.; red). C, In 2I77lox mice, zolpidem does not influence the
power spectra during NREM sleep. Typical epochs of EEG trace are shown. Calibration: A, C, 200
V, 500 ms.
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2F77-2A-Venus, packaged into AAV capsids (Fig. 4A). This
AAV-flex-rev-2F77-2A-Venus was bilaterally injected into the
ventral TMN area of adult HDC-2I77 mice to generate HDC-
2F77 mice (Fig. 4B). The flex switch in the AAV transgene en-
sured that 2F77 expression was restricted to Cre-positive
neurons (Fig. 4A). These mice had bilateral expression of the
2F77-2A-Venus transgene in their TMN area, confined to HDC
neurons in the ventral parts of the TMN (Fig. 4B,C), in an700
m anterior-to-posterior segment (Fig. 4D). The mean number
of AAV-transduced neurons inHDC-2F77 brains, as assessed by
Venus expression, was compared with a count performed on a
brain from an HDC-Cre x Rosa-YFP reporter mouse cross. We
Figure 4. Making histamine neurons selectively sensitive to zolpidem. A, Generating the HDC-2F77 mice: the alleles HDC-Cre and 2I77lox in HDC-2I77 mice, and the AAV flex-switch
transgene construct AAV-flex-rev-2F77-2A-Venus used to selectively label (Venus) and introduce zolpidem sensitivity (2F77) in HDC-2I77 neurons. Open triangles represent loxP sites. Filled
triangles represent lox2272 sites. ITR, Inverted terminal repeats; P, pan-promoter (hdc gene promoter fragment); WPRE, woodchuck post-transcriptional regulatory element. B, Schematic of AAV
microinjection into the TMN area of HDC-2mouse brain. C, Histaminergic neurons labeled by Cre-dependent activation of the AAV-flex-rev-2F77-2A-Venus transgene, detected by immuno-
cytochemistry with EGFP antisera. D, Number of Venus-labeled neurons along the rostrocaudal axis of the posterior hypothalamus, detected by EGFP immunocytochemistry. E, Spontaneous IPSCs
recorded from histaminergic neurons in acute brain slices prepared from the posterior hypothalamus of C57BL/6J (2F77),2I77lox, and HDC-2F77mice before (black) and after 10M zolpidem
(red) application. Traces representpeak-normalized, superimposedaveragewaveforms. For theC57BL/6J (2F77) data, 87eventswere averagedbefore zolpidemand61eventswere averagedafter
zolpidem. For the2I77 lox data, 124 events were averaged before zolpidem and 167 events were averaged after zolpidem. For theHDC-2F77 data, 59 events were averaged before zolpidem and
90 events were averaged after zolpidem. Graphs represent the mean weighted decay times before and after zolpidem application for the different groups of mice. **p 0.002 (paired t test).
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found HDC-Cre x Rosa-YFP mice had 8000 neurons in which
the HDC promoter was active in the TMN area (data not shown).
This could be an overestimate if some of theRosa-YFP expression
originates from the HDC-Cre gene turning on and off during
development. In the adult HDC-2F77 mice, where Venus ex-
pression can only be seen if the HDC-Cre gene is active in the
adult, 7000 Venus-positive cells could be detected. This num-
ber will be an underestimate because it cannot be expected that all
histaminergic neurons in HDC-2I77 mice would be trans-
duced by the AAV-flex-rev-2F77-2A-Venus virus (see below).
On the other hand, counts of cells immunoreactive for histamine
estimated that there were 2500 –3500 such neurons in the mouse
hypothalamus (Parmentier et al., 2002), and 3800 in the rat de-
termined by staining with histidine decarboxylase antibodies (Er-
icson et al., 1987). Given the difference in sensitivity between the
genetic and primary immunoreactive detection methods, our es-
timate of histaminergic neuronal number is approximately in the
same range. The extent of AAV transduction inHDC-2F77mice
was also ascertained by whole-cell voltage-clamp recordings in
acute slices made from the posterior hypothalamus. In the ventral
TMN region, we found that 10 of 16 neurons (62.5%) had re-
stored IPSCs that resembled IPSCs recorded fromC57BL/6J neu-
rons (e.g., Fig. 4E). Of these 16 cells, the remaining 6 still had no
IPSCs (data not shown). Presumably, these six neurons had not
been transduced by AAV-flex-rev-2F77-2A-Venus virus and
were still HDC-2I77 knock-out cells (Zecharia et al., 2012).
We confirmed that the HDC-2F77 histaminergic neurons with
rescued IPSCs also had restored zolpidem sensitivity. Zolpidem
(10 M) applied to C57BL/6 (2F77) histaminergic cells slowed
the IPSC decay by 48 8%, from 30 3 ms (control) to 44 3
ms (zolpidem) (n 5 cells, paired t test, t(4) 7.5, p 0.002; Fig.
4E, left); by contrast, 10 M zolpidem applied to 2I77lox hista-
minergic neurons had no effect on the IPSC decay, being23
4 ms (control) and 24  4 ms (zolpidem) (n  5 cells, paired t
test, t(4)  0.7, p  0.27; Fig. 4E, middle). In contrast, 10 M
zolpidem applied to HDC-2F77 TMN neurons slowed the IPSC
decay by 46  7% from 24  3 ms (control) to 35  5 ms
(zolpidem) (n 6 cells, paired t test, t(5) 5.7, p 0.002; Fig. 4E,
right), the same magnitude of response obtained by applying
zolpidem to C57BL/6J histaminergic neurons (Fig. 4E, left).
The baseline sleep–wake parameters of HDC-2F77 mice did
not differ from 2I77lox or C57BL/6J mice (Table 1). We next
examined whether administering zolpidem systemically toHDC-
2F77 mice induced sleep (Fig. 5). Following a zolpidem (5 mg/
kg, i.p.) injection, the sleep latency of HDC-2F77 mice was
significantly decreased by75 6%, from 45 4 min (saline) to
11 2 min (zolpidem) (n 4; paired t test, t(3) 8, p 0.004]
(Fig. 5A). HDC-2F77 mice spent significantly more time in
NREM sleep (21  2 min) compared with mice injected with
saline (2.8 1.8 min) (n 4; paired t test, t(3) 9.5, p 0.002;
Fig. 5B). However, in the first 45 min after drug injection,
zolpidem-injected HDC-2F77 mice slept for approximately half
as much time as zolpidem-injectedC57BL/6Jmice. Furthermore,
in contrast to zolpidem’s effects in C57BL/6J mice, zolpidem’s
ability to prolong sleep time in HDC-2F77 did not persist be-
yond the first 45 min after injection. So we did not create the full
effect of zolpidem (5 mg/kg) in HDC-2F77 mice. In the sleep
states induced by zolpidem in the HDC-2F77 mice, EEG power
in the zolpidem-induced sleep was not significantly reduced
compared with that occurring in natural NREM sleep (n  4;
paired t test, 2–16 Hz inclusive, t(3)  1.84, p  0.16; Fig. 5B,
inset), which contrasts with the effect of zolpidem on EEG power
inC57BL/6Jmice (Fig. 3A). Examples of the primary EEG record-
ings and sleep-scoring for saline- and zolpidem-injected HDC-
2F77 mice are shown in Figure 5C.
The FC also can contribute to zolpidem-induced sleep
induction but not maintenance
In some circumstances, the FC could help initiate sleep (see Dis-
cussion). To test whether zolpidem might work partly through
this route to induce sedation, we made the FC of 2I77 lox mice
selectively zolpidem-sensitive by genetically swapping zolpidem-
sensitive 2F77 subunits into 2I77 lox frontal cortical neurons,
so generating FC-2F77 mice (Fig. 6A,B). For this, we coinjected
bilaterally a mixture of two AAVs into the FC: AAV-Cre-2A-
2F77 and AAV-flex-rev-EGFP. This produced cotransduced
neurons. The swap works as follows. From the AAV-Cre-2A-
2F77 transgene, the Cre recombinase destroys production of
functional 2I77, and the zolpidem-sensitive 2F77 subunit re-
places it; the second AAV expresses EGFP only if Cre recombi-
nase is present, and thus marks neurons that have been
transduced withAAV-Cre-2A-2F77 (Fig. 6A). We visualized the
transduced area by serial sectioning and then immunocytochem-
istry with GFP antisera (Fig. 6C,D). In all injections, the spread of
transduced cells reached rostral almost to the olfactory bulb and
caudal as far as the primary motor cortex (Fig. 6D).AAV-Cre-2A-
2F77 transgene expression was found in both the frontal motor
cortex and the prefrontal cortical areas (including prelimbic cor-
tex, orbital areas, primary and secondary motor cortices). Maxi-
mally 20% of any given cortical area was transduced, mostly
restricted to the deep layers of cortex, V and VI (Fig. 6C,D). To
confirm that the 2I77 to 2F77 swap had produced zolpidem
sensitivity in pyramidal neurons of FC-2F77 mice, we made
acute slices of M1 and M2 frontal neocortex and performed
whole-cell voltage-clamp recordings on pyramidal neurons from
layers 5 and 6. The neurons expressing the AAV-Cre-2A-2F77
transgene were identified by their primary EGFP signal. Zolpi-
dem (1 M) slowed the decay of IPSCs by 63.5 14% in EGFP-
expressing neurons, from 15.4  1.8 ms (control) to 24.5  2.2
ms (zolpidem) (n 6, paired t test, t(5) 6.4, p 0.001) (Fig. 6E,
right), which was similar to its effect on the IPSCs of C57BL/6
pyramidal neurons (n 6, paired t test, t(5) 8.8, p 0.0003; Fig.
6E, left); by contrast, the decay of IPSCs was unchanged by zol-
pidem (13.2 2.2 ms) in 2I77lox neocortical pyramidal neurons
compared with control solution (12.8 2.2 ms) (n 5, paired t
test, t(4) 1, p 0.4; Fig. 6E, middle).
The baseline sleep–wake parameters of FC-2F77 mice did
not differ from 2I77lox or C57BL/6J mice (Table 1). We tested
whether making FC neurons selectively zolpidem-sensitive was
sufficient to produce a behavioral response in FC-2F77 mice
(Fig. 7). We administered zolpidem (5 mg/kg) to FC-2F77 mice
and found that this reduced latency to NREM sleep (Fig. 7A).
FC-2F77 mice had a 50  14% shorter latency to NREM sleep
(zolpidem: 13 4 min) compared with those injected with saline
4
Figure 5. Selective potentiation of GABA inputs onto histaminergic neurons allows zolpi-
dem to induce and maintain sleep. A, Sleep latencies after saline and zolpidem (5 mg/kg)
injections in HDC-2F77mice. **p 0.004 (paired t test). B, Time spent in NREM sleep in the
first 45 min after saline and zolpidem in HDC-2F77 mice. **p 0.002. B, Inset, Normalized
EEGpower spectra fromHDC-2F77mice following zolpidem(5mg/kg i.p.; red) comparedwith
their natural NREM sleep spectra (blue). Typical epochs of EEG trace are shown. C, EEG power
spectra for HDC-2F77mice injected with saline or 5 mg/kg zolpidem. The spectra are aligned
in register with the / power ratio, the root mean square electromyogram (RMS EMG), the
primary EEG, and the sleep scoring assignments (Wake, NREM, REM). Arrow indicates the time
of saline or zolpidem injection.
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(30 6 min) (Fig. 7A) (n 6; paired t test, t(5) 2.6, p 0.045).
However, zolpidem did not significantly increase NREM time in
FC-2F77 mice compared with those injected with saline (n 6;
paired t test, t(5) 1.5, p 0.2; Fig. 7B). The EEG power of this
sleep following zolpidem administration in FC-2F77 mice did
not differ from natural NREM sleep (n 6, paired t test, 2–16 Hz
inclusive, t(5) 0.95, p 0.39; Fig. 7C). Examples of the primary
EEG recordings and sleep-scoring for saline- and zolpidem-
injected FC-2F77 mice are shown in Figure 8.
The SC do not contribute to zolpidem’s
sleep-inducing actions
Can zolpidem work in any brain area to induce NREM sleep? To
test this, we looked at the SC (Fig. 9). The SCs are not associated
with induction or maintenance of NREM sleep but do regulate
eye movements and visual attention and also communicate with
REM sleep-promoting areas. We made the SC of 2I77lox mice
selectively zolpidem-sensitive. SC-2F77 mice were generated by
bilaterally injecting AAV-Cre-2A-2F77 into the SC of 2I77lox
Figure 6. Making frontal cortical neurons selectively sensitive to zolpidem. A, Generating the FC-2F77mice: the2I77lox allele and the two AAVs, AAV-Cre-2A-2F77 and AAV-flex-rev-EGFP,
used tomake the zolpidem-insensitive2I77 to zolpidem-sensitive2F77 subunit swap in2I77 lox mice in the FC. CMV, Cytomegalovirus enhancer/promoter; ITR, inverted terminal repeats; pA,
polyadenylation signal; WPRE, woodchuck post-transcriptional regulatory element. B, The two AAVs were mixed and coinjected into the FC of2I77lox mice. C, Overall expression of the AAV-Cre-
2A-2F77 transgene inpyramidal neurons (e.g., in layerV shownhere)wasdetectedbyEGFP immunocytochemistry.D, Percentageareaof transduced frontal neocortical sites along the rostrocaudal
axis. E, Peak normalized spontaneous IPSCs recorded from cortical pyramidal neurons before (black) and after 1M zolpidem (red) from C57BL/6J (2F77),2I77lox, and FC-2F77 neurons. Traces
are superimposed averages. To construct these, 251 events (before zolpidem) and 175 events (after zolpidem)were averaged for C57BL/6Jneurons; 74 events (before zolpidem) and 71 events (after
zolpidem)were averaged for2I77 lox neurons; 247 events (before zolpidem) and155 events (after zolpidem)were averaged forHDC-2F77neurons. Graphs representmeanweighted decay times
of IPSCs before and after 1M zolpidem in C57BL/6J (2F77; ***p 0.0003, paired t test),2I77 lox and FC-2F77 (layer 5/6) pyramidal neurons (***p 0.001, paired t test).
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mice (Fig. 9A,B). AAV-Cre-2A-2F77 transgene expression, de-
tected by staining with Cre recombinase antisera (Fig. 9C), was
found throughout the layers of the SC. The baseline sleep–wake
parameters of SC-2F77 mice did not differ from 2I77lox or
C57BL/6J mice (Table 1). After zolpidem (5 mg/kg, i.p.) injec-
tion, the latency to NREM sleep (44 10 min) of SC-2F77 mice
did not differ from that following a saline injection (37 2 min)
(Fig. 9E;n 4; paired t test, t(3) 0.8, p 0.48). The NREM sleep
time of SC-2F77 mice was also not increased during the first 45
min after zolpidem administration compared with saline (n 4;
paired t test, t(3)  0.07, p  0.95; Fig. 9F). Zolpidem did not
change the proportion of REM sleep in SC-2F77mice in the first
45 min after injection.
Discussion
We have previously suggested that sedatives produce sleep by
interacting with the NREM sleep-inducing circuitry, changing
activity in the hypothalamic and brainstem circuits that globally
govern arousal (Nelson et al., 2002; Franks, 2008; Lu et al., 2008;
Zhang et al., 2015). We show here that this seems to be the case for
zolpidem, too. By using a pharmacogenetic method that probes
endogenous GABA tone, we found that selectively augmenting
the active GABA input onto hypothalamic histamine neurons by
systemic zolpidem administration decreased NREM sleep latency
and enhanced sleep time but without reducing power in the
EEG. As well as revealing a potential site for zolpidem’s sleep-
promoting actions in vivo, our pharmacogenetic findings support
the hypothesis that the initiation of natural NREM sleep could
arise by increased and sustained inhibition onto histaminergic
neurons (Nitz and Siegel, 1996; Sherin et al., 1996, 1998).
Clinical features of zolpidemmimicked in mice with brain
regions selectively zolpidem-sensitive
Positive GABAA receptor modulators are often good at inducing
sleep (Lancel and Steiger, 1999; Winsky-Sommerer, 2009; Nutt
and Stahl, 2010; Rye et al., 2012). Zolpidem’s pharmacokinetics
make it effective for treating insomnia: it maximally occupies its
receptor sites minutes after entering the blood, causing sleep
quickly, but its short plasma half-life limits “hangovers” (Bena-
vides et al., 1988). In controlled clinical settings, zolpidem’s main
effect on people is to reduce sleep latency; but overall zolpidem
performs no better than placebo in sleep maintenance, wake time
after sleep onset, or number of awakenings (Greenblatt and Roth,
2012). By these measures, zolpidem’s key clinical action, reduc-
tion of sleep latency, is mimicked by increasing inhibition onto
histaminergic neurons. However, the NREM sleep induced by
zolpidem in humans and wild-type rodents does not entirely re-
semble natural sleep because “zolpidem sleep” has diminished
power in the EEG compared with natural NREM sleep for fre-
quencies 5 Hz in rodents (Kopp et al., 2004; Alexandre et al.,
2008), and most frequencies in humans (Landolt et al., 2000). It is
not clear whether this diminished EEG power is a good or bad
feature of zolpidem-induced sleep. But in the HDC-2F77 and
FC-2F77 mice, the power of zolpidem-evoked NREM sleep was
the same as natural NREM sleep, so these “power-decreasing”
effects of zolpidem must originate in other brain areas. This
knowledge may be useful for designing sedatives that produce a
more natural sleep.
Zolpidem can induce NREM sleep by selectively inhibiting
histaminergic neurons
Despite having a 20-fold higher affinity at 12-containing
GABAA receptors (Pritchett and Seeburg, 1990), which are the
most widely expressed and abundant type of GABAA receptors in
the brain (Pritchett et al., 1989; Wisden et al., 1992; McKernan
and Whiting, 1996), zolpidem (5 mg/kg) induces sleep through
the 22 and/or 32 GABAA receptors (Kopp et al., 2004).
The 1-containing receptors are, instead, responsible for the de-
crease in EEG power across most frequencies5 Hz in zolpidem-
evoked sleep (Kopp et al., 2004). We might also expect that
zolpidem’s effects, such as sleep, result from additive slowing of
IPSCs on cell types with 2 and/or 3 subunits throughout the
brain. But this is not the case. Prolonging IPSCs on just histamin-
ergic neurons is enough to induce and maintain sleep, although
not to the full extent generated by zolpidem in wild-type
C57BL/6J mice. Zolpidem is probably effective at histamine neu-
rons because of their hub-like nature and their ability to promote
arousal and wakefulness (Haas and Panula, 2003). Although
there are relatively few histamine neurons, between 3000 and
7000 in the mouse, their axons ascend and descend from the
TMN, coursing throughout the brain, coreleasing histamine and
GABA to give balanced arousal (Wada et al., 1991; Haas and
Panula, 2003; Yu et al., 2015). Thus, acutely inhibiting the “his-
tamine hub” by zolpidem will cause histamine levels to fall
throughout the brain and sleep to ensue. This fits with previous
pharmacological data that infusing GABA agonists into the TMN
area induces sleep (Lin et al., 1989; Nitz and Siegel, 1996), and
Figure 7. The FC contributes to zolpidem’s ability to reduce sleep latency.A, Sleep latencies.
B, Sleep times in the first 45 min after either saline or zolpidem (5 mg/kg) for FC-2F77mice.
*p 0.045 (paired t test). C, Normalized EEG power spectrum from FC-2F77mice following
zolpidem (5 mg/kg i.p.; red) compared with their natural NREM sleep spectrum (blue).
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that GABA/galanin neurons in the lateral preoptic neurons,
which send axons to the TMN, increase their activity during sleep
(Sherin et al., 1996, 1998). Histaminergic neurons principally
express 132 and 232 GABAA receptors (Fritschy and
Mohler, 1995; Sergeeva et al., 2002; Zecharia et al., 2009, 2012;
May et al., 2013). Thus, these2-containing GABAA receptors on
the histaminergic neurons are likely candidates for a part of zol-
pidem’s sleep-inducing actions in vivo. The 1-containing
GABAA receptors that cause zolpidem to reduce EEG power must
be on other types of neurons elsewhere.
Zolpidem can initiate sleep top-down from the FC
We found that zolpidem can act in the frontal neocortex to re-
duce sleep latency, although the effect was not as large as for the
histaminergic neurons, and sleep time was also not increased.
Other data also link the frontal and preFC and behavioral sleep:
sleep can initiate top-down if the FC is stimulated at 4 Hz
(Penaloza-Rojas et al., 1964; Lineberry and Siegel, 1971); slow
waves initiate in frontal neocortex (Massimini et al., 2004; Vya-
zovskiy et al., 2009); and in human aging, atrophy of the medial
prefrontal cortex correlates with disrupted NREM slow waves
(Mander et al., 2013).
Pharmacogenetic manipulation of GABA inputs versus
receptor knock-outs, acute versus chronic
There are several caveats to consider when interpreting our re-
sults. The first point is that acute inhibition of one area in the
brain could affect circuit dynamics in other areas (Otchy et al.,
2015). The brain’s dense interconnectivity could cloud, rather
than reveal, the function of the inhibited region and so “transient
circuit manipulations may have their own interpretive difficul-
ties” (Otchy et al., 2015). This could indicate that zolpidem does
not normally induce sleep by enhancing inhibition on histamine
neurons but only does so in this particular artificial situation
whereby the histamine neurons are made uniquely sensitive to
zolpidem in the HDC-2F77 mice. The second point is that dif-
Figure 8. EEG power spectra and sleep scoring for zolpidem-induced sleep in FC-2F77 mice. EEG power spectra for FC-2F77 mice injected with saline or 5 mg/kg zolpidem. The spectra are
aligned in register with the/ power ratio, the root mean square electromyogram (RMS EMG), the primary EEG, and the sleep scoring assignments (Wake, NREM, REM). Arrow indicates the time
of saline or zolpidem injection.
Uygun, Ye et al. • Zolpidem’s Sites of Action In Vivo J. Neurosci., November 2, 2016 • 36(44):11171–11184 • 11181
ferent results are often produced by chronic or acute ablations
(Wisden et al., 2009; Otchy et al., 2015). Genetic ablation of the
GABAA receptor 2 subunit from histaminergic neurons did not
affect normal sleep over a 24 h period, although it did produce the
more subtle effect of preventing the mice settling down and going
to sleep in a new environment; in other words, removing synaptic
GABAA receptors from histaminergic neurons lengthened the
latency to NREM sleep (Zecharia et al., 2012), and this fits with
our new data that, going in the opposite direction, enhancing
IPSCs with zolpidem on these neurons shortens the latency to
NREM sleep. Nevertheless, it remains remarkable that fast GABA
input to the histamine neurons is dispensable for controlling the
basic sleep–wake cycle. Similar to our results on histamine neu-
rons, we found that chronic ablation versus acute pharmacoge-
netic modulation of GABA inputs on cerebellar Purkinje neurons
also produced different results: mice with zolpidem-sensitive
GABAA receptors selectively expressed in Purkinje neurons had
acute ataxia after being given zolpidem, and so we concluded that
ongoing GABA input onto Purkinje cells modulates motor con-
trol (Wulff et al., 2007; Wisden et al., 2009); by contrast, knocking
out the 2 subunit selectively and permanently from Purkinje
cells, and the consequent removal of fast synaptic responses to
GABA, did not produce overt ataxia, but only a subtle deficit in
limb coordination (Vinueza Veloz et al., 2015). To explain the
large difference in behavioral phenotype produced by acute zol-
pidem modulation of Purkinje cells and chronic ablation of fast
inhibitory input, we hypothesized that the cerebellar circuitry
with chronically removed synaptic GABA input on Purkinje cells
Figure 9. The SC do not contribute to zolpidem-induced sleep. A, Generating the SC-2F77mice: the AAV-Cre-2A-2F77 transgene used to make the zolpidem-insensitive2I77 to zolpidem-
sensitive 2F77 subunit swap in 2I77lox mice. CTX, Neocortex; CMV, cytomegalovirus enhancer/promoter; ITR, inverted terminal repeats; pA, polyadenylation signal; WPRE, woodchuck post-
transcriptional regulatory element. B, Bilateral AAV-Cre-2A-2F77 microinjection into the SC of 2I77lox mouse brain to generate SC-2F77 mice. C, Detection of AAV-Cre-2A-2F77 transgene
expression in the SC by anti-Cre immunohistochemistry. CTX, Neocortex. D, Percentage area of AAV-transduced SC along the rostrocaudal axis, deduced by counting Cre-positive cells. E, Sleep
latency. F, Sleep time after saline and zolpidem (5 mg/kg) injections in SC-2F77mice.
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had undergone adaptation (Wulff et al., 2007; Wisden et al.,
2009). We think the weak phenotypes produced by 2 subunit
ablation from Purkinje cells and histaminergic cells, and the
contrasting strong phenotypes obtained by acute manipulation
with zolpidem are analogous: the pharmacogenetic “zolpidem
method” unmasks the acute role for GABA in modulating hista-
minergic neurons, whereas HDC-2 mice have undergone
compensatory changes. Acute zolpidem manipulation in HDC-
2F77 mice produces the “true” result.
In conclusion, zolpidem has rather subtle effects on synaptic
IPSCs. Typically, it prolongs them by 50%. We might have
expected that zolpidem induces sleep by potentiating IPSCs ev-
erywhere in the brain; the net effect would be behavioral sleep.
But instead we have shown that zolpidem can induce sleep by
strengthening GABA signaling on just one cell type (histamine
neurons). Normally, the NREM sleep induced by zolpidem does
not resemble natural sleep; the drug produces a lower power in
most frequencies of the EEG during NREM sleep. But via hista-
mine neurons, zolpidem can induce sleep without reducing the
EEG power of the sleep. This knowledge could help design drugs
that induce a more natural sleep.
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